Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic H... (1200 Q4w treatment group achieved ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C

Date:11/5/2007

1200 Q4w

treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a

administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

61.0% of those in the Albuferon 1200 Q4w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a administered once every week.

-- Among all treatment-adherent patients in the Albuferon 1200 Q4w

treatment group, 62.0% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- The rate of discontinuations due to adverse events was 12.1% in the

Albuferon 1200 Q4w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy.

-- The number of patients experiencing severe hematologic adverse events

was significantly lower in the Albuferon 1200 Q4w treatment group

(10.3%, vs. 20.2% for peginterferon alfa-2a, p<0.05).

Higher doses of Albuferon administered every four weeks, in combination with ribavirin, will be explored in a separate Phase 2b trial conducted by Novartis, which is expected to begin by year-end 2007.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commerci
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials

Post Your Comments:

(Date:12/15/2009)... OBP Medical Inc. declares victory in the battle ... hospitals. ,, Doctors at Newton-Wellesley Hospital in Newton, ... Medical,s Under Johnnies(TM) on patients, comfort and satisfaction ... is comparing patients, perception of comfort, privacy and ... Johnnies(TM) against the traditional hospital gown and socks. ...

(Date:12/14/2009)... Dec. 14 Embarrassing and sometimes uncomfortable colonoscopies ... National researchers are taking note of a new screening ... process. The Knoxville-based company, EDP Biotech Corporation ... ColoMarker, an affordable medical device doctors can use to ... "When you consider that 30% of colon cancer ...

(Date:12/14/2009)... 14 The board of directors of Eli ... declared a dividend for the first quarter of 2010 ... ,, The dividend is payable March 10, 2010 ... on ,, February 12, 2010. ,, Lilly, a ... pharmaceutical products by applying the latest research from its ...

[0] Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc.[0] EDP Biotech Takes Next Step in the Development of ColoMarker [0] Lilly Declares First-Quarter 2010 Dividend

... Vical Incorporated (Nasdaq:,VICL) today reported financial results for ... quarter of 2007 were $3.1 million, compared with,revenues of ... net loss for,the second quarter of 2007 was $8.2 ... of $3.2 million, or $0.11 per share, for the ...

... Progression Rates Are the ... Resources, WALTHAM, Mass., Aug. 7 Decision ... advisory firms focusing on pharmaceutical,and healthcare issues, finds ... Sutent as the clinical gold standard for,the treatment ...

Other Medicine Technology:Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6 Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma 2

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma

(Date:12/14/2009)... Young Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, and ... -- Nearly all unmarried young adults ages 18-29 believe ... men and 86% of women) and say that it ... now (86% of men and 88% of women), according ... Prevent Teen and Unplanned Pregnancy. Even so: ,, ...

(Date:12/14/2009)... HOLLYWOOD, Fla., Dec. 14 Abbott ... a definitive agreement to acquire STARLIMS Technologies ... provider of laboratory information management systems, for ... The acquisition strengthens Abbott,s competitive position in ... applications to help laboratories efficiently store, retrieve ...

(Date:12/14/2009)... The National Organization for Rare Disorders (NORD) today called ... and annual health insurance caps. In a full-page ... widely on Capitol Hill, NORD said the current Senate ... to continue for most Americans, contrary to what many ... and welcomes the promises made by President Obama and ...

(Date:12/14/2009)... 13 years under government controlled health care, before moving to the ... engagements and in his new book, Health Reform: The End of ... a system and its threat to real health care! , ... ... a diagnostic radiologist from Minnesota, warns Americans not to sell out ...

(Date:12/14/2009)... Legislation Critical to Stemming Tide of Tens of ... ,, WASHINGTON, Dec. 14 Legislation approved ... exchange will be crucial in helping to reduce ... occurring each year in the United States, the ... today. The provision was included in the ...

Breaking Medicine News(10 mins):Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4 Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2 Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2 Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2

[1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference [0] Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems [0] NORD Calls for Immediate End to Lifetime Insurance Caps [2] Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America [0] NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange

... say , moms-to-be who are carrying girls are more ... than pregnant asthmatic women carrying boys. Doctors speculate female ... inflammation of the mother’s airways that somehow worsens the ... of asthmatic women who were pregnant with boys were ...

... an effective combination treatment for patients with advanced prostate ... cancer death in men and// according to the American ... of prostate cancer diagnosed this year. ,The ... steroid). Researchers say the treatment has shown promise for ...

... findings from a new study researchers say women who are ... might be missing out // on getting screened for the ... might now also need to add colorectal screenings to the ... Centers for Disease Control and Prevention’s 2001 Behavioral Risk Factors ...

... DVT ) is a blood clot that develops deep in ... to the lung. // ,People who require prolonged ... and blood circulation ,especially patients in intensive care and patient ... studies have shown that in critically ill patients , a ...

... Two new studies show high levels of amino acid ... of homocysteine have long been // associated with an ... levels are also known to be associated with homocystinuria, ... in two separate studies, high levels have also been ...

... cycle consisting of periods of growth (anagen), regression ... brief activation of ?-catenin in // telogen-phase adult ... phase. Scientists have discovered that the transient activation ... hair growth. ,Previous work has implicated ...

Other Medicine News:Health News:New Hair in 15 Days Could Now Be A Possibility Say Researchers 2

Controlling Asthma during Pregnancy Hope For Patients With Prostate Cancer Women not Getting Screened Adequately Blood Clots Could Be Very Fatal Blood Tests Can Help Detect Osteoporosis Early In Life New Hair in 15 Days Could Now Be A Possibility Say Researchers

Flat tip, bare fiber, no cooling, polished SMA 905, 3 meters long. Sold in boxes of five. Each part is individually packaged in sterile Tyvek bags....

... unique lateral fiber possessing a ... rotated to any one of ... fibers in one. The fiber ... and coagulation and back to ...

... Ultrafin™ Stirrup is the latest ... stirrup features a roomier boot ... up to an 800 pound ... to position heavy legs more ...

... assist stirrups are designed to travel a full ... They lock tight wherever you release the rotating ... are done at the handle with no need ... socket. The rotation of system was designed to ...

Medicine Products:

Megabeam Non-Contact Fibers for Holmium Lasers QuadraLase™Ultrafin™ Stirrup Lift Assist Stirrup System

Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic H...(1200 Q4w treatment group achieved ...),Health